The prognostic impact of EGFR, ErbB2 and MET gene amplification in human gastric carcinomas as measured by quantitative Real-Time PCR

Journal of Cancer Research and Clinical Oncology

Volumn 141, Issue 11, 2015, Pages 1945-1952

  Janbabai, Ghasem ^a   Oladi, Ziaeddin ^a   Farazmandfar, Touraj ^a,b,c   Taghvaei, Tarang ^a   Naghshvar, Farshad ^d  

^a MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b GOLESTAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

EGFR; ErbB2; Gastric cancer; Gene amplification; MET

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN; MESSENGER RNA; EGFR PROTEIN, HUMAN; ERBB2 PROTEIN, HUMAN; MET PROTEIN, HUMAN; SCATTER FACTOR RECEPTOR;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION COEFFICIENT; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MET GENE; OVERALL SURVIVAL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; STOMACH CARCINOMA; TUMOR DIFFERENTIATION; TUMOR GENE; TUMOR VOLUME; BIOSYNTHESIS; COPY NUMBER VARIATION; GENETICS; MIDDLE AGED; STOMACH TUMOR;

DNA COPY NUMBER VARIATIONS; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; HUMANS; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-MET; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RNA, MESSENGER; STOMACH NEOPLASMS;

EID: 84951569781     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-015-1965-7     Document Type: Article

References (42)

1. Al-Batran S-E, Hartmann JT, Hofheinz R et al (2008) Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol 19:1882–1887. doi:10.1093/annonc/mdn403
2. Albertson DG (2006) Gene amplification in cancer. Trends Genet 22:447–455. doi:10.1016/j.tig.2006.06.007
3. Arteaga CL (2002) Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist 7(Suppl 4):31–39. doi:10.1634/theoncologist.7-suppl_4-31
4. Atmaca A, Werner D, Pauligk C et al (2012) The prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancer. BMC Cancer 12:524. doi:10.1186/1471-2407-12-524
5. Bang Y-J, Van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687–697. doi:10.1016/S0140-6736(10)61121-X
6. Beroukhim R, Mermel CH, Porter D et al (2010) The landscape of somatic copy-number alteration across human cancers. Nature 463:899–905. doi:10.1038/nature08822
7. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF (2003) Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4:915–925. doi:10.1038/nrm1261
8. Casalini P, Iorio MV, Galmozzi E, Ménard S (2004) Role of HER receptors family in development and differentiation. J Cell Physiol 200:343–350. doi:10.1002/jcp.20007
9. Chen JD, Kearns S, Porter T et al (2001) MET mutation and familial gastric cancer. J Med Genet 38:E26. doi:10.1136/jmg.38.8.e26
10. Cunningham D, Okines AFC, Ashley S (2010) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 362:858–859. doi:10.1056/NEJMc0911925
11. Galizia G, Lieto E, Orditura M et al (2007) Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery. World J Surg 31:1458–1468. doi:10.1007/s00268-007-9016-4
12. Gamboa-Dominguez A, Dominguez-Fonseca C, Quintanilla-Martinez L et al (2004) Epidermal growth factor receptor expression correlates with poor survival in gastric adenocarcinoma from Mexican patients: a multivariate analysis using a standardized immunohistochemical detection system. Mod Pathol 17:579–587. doi:10.1038/modpathol.3800085
13. García I, Vizoso F, Martín A et al (2003) Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer. Ann Surg Oncol 10:234–241. doi:10.1245/ASO.2003.05.010
14. Graziano F, Galluccio N, Lorenzini P et al (2011) Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer. J Clin Oncol 29:4789–4795. doi:10.1200/JCO.2011.36.7706
15. Huang W-T, Chuang S-S (2013) High MET gene copy number predicted poor prognosis in primary intestinal diffuse large B-cell lymphoma. Diagn Pathol 8:16. doi:10.1186/1746-1596-8-16
16. Jemal A, Bray F, Center MM et al (2011) Global cancer statistics. CA Cancer J Clin 61:69–90. doi:10.3322/caac.20107
17. Junttila TT, Laato M, Vahlberg T et al (2003) Identification of patients with transitional cell carcinoma of the bladder overexpressing ErbB2, ErbB3, or specific ErbB4 isoforms: real-time reverse transcription-PCR analysis in estimation of ErbB receptor status from cancer patients. Clin Cancer Res 9:5346–5357
18. Kato H, Arao T, Matsumoto K et al (2013) Gene amplification of EGFR, HER2, FGFR2 and MET in esophageal squamous cell carcinoma. Int J Oncol 42:1151–1158. doi:10.3892/ijo.2013.1830
19. Kawakami H, Okamoto I, Arao T et al (2013) MET amplification as a potential therapeutic target in gastric cancer. Oncotarget 4:9–17
20. Kim MA, Lee HS, Lee HE et al (2008) EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number. Histopathology 52:738–746. doi:10.1111/j.1365-2559.2008.03021.x
21. Kim J-S, Kim M-A, Kim TM et al (2009) Biomarker analysis in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival. Br J Cancer 100:732–738. doi:10.1038/sj.bjc.6604936
22. Kuniyasu H, Yasui W, Yokozaki H et al (1993) Aberrant expression of c-met mRNA in human gastric carcinomas. Int J Cancer 55:72–75
23. Lee JH, Han SU, Cho H et al (2000) A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene 19:4947–4953
24. Lee J, Seo JW, Jun HJ et al (2011) Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target. Oncol Rep 25:1517–1524. doi:10.3892/or.2011.1219
25. Lee HE, Kim MA, Lee HS et al (2012) MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome. Br J Cancer 107:325–333. doi:10.1038/bjc.2012.237
26. Lieto E, Ferraraccio F, Orditura M et al (2008) Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. Ann Surg Oncol 15:69–79. doi:10.1245/s10434-007-9596-0
27. Liu X, Newton RC, Scherle PA (2010) Developing c-MET pathway inhibitors for cancer therapy: progress and challenges. Trends Mol Med 16:37–45. doi:10.1016/j.molmed.2009.11.005
28. Matsubara J, Yamada Y, Nakajima TE et al (2008) Clinical significance of insulin-like growth factor type 1 receptor and epidermal growth factor receptor in patients with advanced gastric cancer. Oncology 74:76–83. doi:10.1159/000139127
29. Matsumoto K, Arao T, Hamaguchi T et al (2012) FGFR2 gene amplification and clinicopathological features in gastric cancer. Br J Cancer 106:727–732. doi:10.1038/bjc.2011.603
30. Nakajima M, Sawada H, Yamada Y et al (1999) The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 85:1894–1902
31. Park WS, Oh RR, Kim YS et al (2000) Absence of mutations in the kinase domain of the Met gene and frequent expression of Met and HGF/SF protein in primary gastric carcinomas. Apmis 108:195–200
32. Sakai K, Mori S, Kawamoto T et al (1986) Expression of epidermal growth factor receptors on normal human gastric epithelia and gastric carcinomas. J Natl Cancer Inst 77:1047–1052. doi:10.1093/jnci/77.5.1047
33. Seruca R, Suijkerbuijk RF, Gärtner F et al (1995) Increasing levels of MYC and MET co-amplification during tumor progression of a case of gastric cancer. Cancer Genet Cytogenet 82:140–145. doi:10.1016/0165-4608(95)00033-L
34. Song HS, Do YR, Kim IH et al (2004) Prognostic significance of immunohistochemical expression of EGFR and C-erbB-2 oncoprotein in curatively resected gastric cancer. Cancer Res Treat 36:240–245. doi:10.4143/crt.2004.36.4.240
35. Stuart D, Sellers WR (2009) Linking somatic genetic alterations in cancer to therapeutics. Curr Opin Cell Biol 21:304–310. doi:10.1016/j.ceb.2009.02.001
36. Tahara E (1995) Genetic alterations in human gastrointestinal cancers. The application to molecular diagnosis. Cancer 75:1410–1417
37. Takeda M, Arao T, Yokote H et al (2007) AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor. Clin Cancer Res 13:3051–3057. doi:10.1158/1078-0432.CCR-06-2743
38. Tsujimoto H, Sugihara H, Hagiwara A, Hattori T (1997) Amplification of growth factor receptor genes and DNA ploidy pattern in the progression of gastric cancer. Virchows Arch 431:383–389. doi:10.1007/s004280050115
39. Van Cutsem E, Moiseyenko VM, Tjulandin S et al (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24:4991–4997. doi:10.1200/JCO.2006.06.8429
40. Vogel CL, Cobleigh MA, Tripathy D et al (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719–726. doi:10.1200/JCO.20.3.719
41. Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127–137. doi:10.1038/35052073
42. Yk W, Gao CF, Yun T et al (2011) Assessment of ERBB2 and EGFR gene amplification and protein expression in gastric carcinoma by immunohistochemistry and fluorescence in situ hybridization. Mol Cytogenet 4:14. doi:10.1186/1755-8166-4-14